Production (Stage)
Ensysce Biosciences, Inc.
ENSC
$2.07
-$0.07-3.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.95% | 24.74% | 37.09% | 42.88% | 54.58% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -98.28% | 267.01% | -- | 61.02% | 58.30% |
| Total Other Non-Cash Items | -81.19% | -69.45% | 198.62% | -61.76% | -75.21% |
| Change in Net Operating Assets | 165.42% | 10.12% | -369.83% | -806.35% | -138.58% |
| Cash from Operations | 45.17% | 30.40% | 30.42% | 41.51% | 41.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -78.69% | -78.69% |
| Total Debt Repaid | 81.91% | 40.92% | 65.19% | 63.28% | 34.12% |
| Issuance of Common Stock | -58.80% | -54.66% | -70.82% | -83.83% | 30.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -43.99% | 1,581.87% | 781.75% | 527.33% | 639.38% |
| Cash from Financing | -56.64% | 12.85% | 21.60% | -58.40% | 13.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.69% | 217.51% | 188.50% | -3,039.14% | 128.31% |